Latest Commercialisation News

Nufarm reported a mixed 1H25 result with a strong rebound in crop protection profits contrasting a steep decline in seed technologies earnings, prompting a strategic review of the latter business.

Ardea Resources has received a $1.2 million R&D tax incentive rebate from the Australian Government, reinforcing its innovative work at the Kalgoorlie Nickel Project and strengthening its financial position.

Nanollose has successfully placed the $1.05 million shortfall from its recent entitlement offer, bolstering its capital to advance production and commercialisation of its innovative biomaterials.

Dotz Nano Limited has announced a A$1.2 million private placement at a discounted share price, accompanied by options, to bolster working capital and support the commercialisation of its carbon capture technology.

Green360 Technologies has successfully produced high-quality metakaolin from its kaolin resources, surpassing industry benchmarks and initiating commercial-scale trials with PERMAcast to validate its low-carbon cement formulations.

ADX Energy has formalised licence amendments and identified four drill-ready shallow gas prospects in Upper Austria, targeting Q4 2025 for initial drilling. The company is advancing farm-in discussions to capitalise on a low-risk, pipeline-proximate gas opportunity in a sought-after European market.

HeraMED faces a setback as Broward Health discontinues its HeraCARE platform amid Medicaid funding cuts, prompting a strategic pivot with new leadership and partnerships to accelerate US growth.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.

Archer Materials has teamed up with UK-based Paragraf to fast-track development of its Biochip sensor for at-home chronic kidney disease testing, aiming to enhance accuracy and product readiness over six months.

Zenith Minerals has completed a pivotal drilling campaign at its Dulcie Far North Gold Project, confirming substantial gold mineralisation and extending resource potential. An updated Mineral Resource Estimate is expected soon, underpinning the company’s development ambitions.

Osteopore Limited has increased its capital raise by drawing down an additional A$500,000 on its Tranche 1 redeemable convertible notes, bringing total subscriptions to A$3.5 million. The funds will support ongoing operations and future growth initiatives.

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.